Sector: Healthcare | Industry: Biotechnology & Medical Research |
Company Contact | |
Address: | 130 3851 Shell Road RICHMOND BC V6X 2W2 |
Tel: | N/A |
Website: | https://www.biomarkdiagnostics.com |
IR: | See website |
Key People | ||
N/A |
Business Overview |
BioMark Diagnostics Inc. is a liquid biopsy company. The Company is developing a molecular diagnostics technology platform, which leverages the power of metabolomics and machine learning algorithms to bring new cancer diagnostics to market and improve cancer prognosis by allowing physicians to detect carcinomas in the pre-symptomatic stages. The technology can also be used for measuring response to treatment and potentially for serial monitoring of cancer survivors. Its cancer diagnostics technology platform leverages Omics and machine learning with a focus on cancers that are hard to detect and treat. Its liquid biopsy assay detects Spermidine/spermine N-acetyltransferase 1 (SSAT1). SSAT1 is an enzyme with elevated levels in numerous cancers. It has also developed a new high powered liquid biopsy metabolic panel assay. The new metabolic assay is instrumental for early-stage diagnosis of lung cancer. The liquid biopsy metabolic panel has demonstrated clinical detections. |
Financial Overview |
For the nine months ended 31 December 2023, BioMark Diagnostics Inc revenues increased 9% to C$123K. Net loss decreased 23% to C$1M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Lower net loss reflects Share-based compensation decrease of 74% to C$84K (expense), Int exp on Financial Lease Liabilitie decrease of 29% to C$41K (expense). |
Reporting Currency: | Canadian Dollars |
Enterprise value: | $27.11M as of Dec 31, 2023 |
Annual revenue (TTM): | $0.16M as of Dec 31, 2023 |
EBITDA (TTM): | -$1.26M as of Dec 31, 2023 |
Net annual income (TTM): | -$1.54M as of Dec 31, 2023 |
Free cash flow (TTM): | -$0.95M as of Dec 31, 2023 |
Net Debt Last Fiscal Year: | $0.77M as of Dec 31, 2023 |
Shares outstanding: | 90,886,229 as of Dec 31, 2023 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |